Literature DB >> 12152677

Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.

Joyce Curvers1, M Christella L G D Thomassen, Janet Rimmer, Karly Hamulyak, Jan van der Meer, Guido Tans, F Eric Preston, Jan Rosing.   

Abstract

BACKGROUND: Several hereditary and acquired risk factors for venous thromboembolism (VTE) are associated with impaired down-regulation of thrombin formation via the protein C pathway. To identify individuals at risk, functional tests are needed that estimate the risk to develop venous thrombosis.
METHOD: We determined the effects of hereditary and acquired risk factors of venous thrombosis on an APC resistance test that quantifies the influence of APC on the time integral of thrombin formation (the endogenous thrombin potential, ETP) initiated in plasma via the extrinsic coagulation pathway. APC sensitivity ratios (APCsr) were determined in plasma from carriers of factor V(Leiden) (n = 56) or prothrombin G20210A (n = 18), of individuals deficient in antithrombin (n = 9), protein C (n = 7) or protein S (n = 14) and of women exposed to acquired risk factors such as hormone replacement therapy (n = 49), oral contraceptive use (n = 126) or pregnancy (n = 35). We also analysed combinations of risk factors (n = 60).
RESULTS: The thrombin generation-based APC resistance test was sensitive for the factor V(Leiden) and prothrombin G20210A mutation, to protein S deficiency, hormone replacement therapy, oral contraceptive use and pregnancy. The assay was not influenced by antithrombin or protein C deficiency. The presence of more than one risk factor of venous thrombosis resulted in more pronounced APC resistance. The APCsr of individuals with a single or combined risk factors of VTE correlated well with reported risk increases.
INTERPRETATION: The thrombin generation-based APC resistance test identifies individuals at risk for venous thrombosis due to acquired risk factors and/or hereditary thrombophilic disorders that affect the protein C pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12152677

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  Thrombin generation test as a marker for high risk venous thrombosis pregnancies.

Authors:  Bérangère S Joly; Bénédicte Sudrié-Arnaud; Virginie Barbay; Jeanne-Yvonne Borg; Véronique Le Cam Duchez
Journal:  J Thromb Thrombolysis       Date:  2018-01       Impact factor: 2.300

2.  Kallikrein augments the anticoagulant function of the protein C system in thrombin generation.

Authors:  Jun Wan; Nadira Vadaq; Joke Konings; Martin Jaeger; Vinod Kumar; Bas de Laat; Leo Joosten; Mihai G Netea; Andre J van der Ven; Philip G de Groot; Quirijn de Mast; Mark Roest
Journal:  J Thromb Haemost       Date:  2021-09-28       Impact factor: 16.036

Review 3.  Modeling thrombin generation: plasma composition based approach.

Authors:  Kathleen E Brummel-Ziedins; Stephen J Everse; Kenneth G Mann; Thomas Orfeo
Journal:  J Thromb Thrombolysis       Date:  2014-01       Impact factor: 2.300

4.  Continuous thrombin generation in whole blood: New applications for assessing activators and inhibitors of coagulation.

Authors:  Shannon M Prior; Kenneth G Mann; Kalev Freeman; Saulius Butenas
Journal:  Anal Biochem       Date:  2018-05-07       Impact factor: 3.365

Review 5.  A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis.

Authors:  Marcus D Lancé
Journal:  Thromb J       Date:  2015-01-12

6.  Platelet-primed interactions of coagulation and anticoagulation pathways in flow-dependent thrombus formation.

Authors:  Sanne L N Brouns; Johanna P van Geffen; Elena Campello; Frauke Swieringa; Paolo Simioni; Johan W M Heemskerk; Luca Spiezia; René van Oerle; Isabella Provenzale; Remco Verdoold; Richard W Farndale; Kenneth J Clemetson; Henri M H Spronk; Paola E J van der Meijden; Rachel Cavill; Marijke J E Kuijpers; Elisabetta Castoldi
Journal:  Sci Rep       Date:  2020-07-17       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.